Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes
Bandaranayake T, Radcliffe C, Cvercko M, Golden M, Hao R. Experience with expanded use of oritavancin in a tertiary hospital: indications, tolerability and outcomes. JAC-Antimicrobial Resistance 2024, 6: dlae174. PMID: 39493938, PMCID: PMC11524893, DOI: 10.1093/jacamr/dlae174.Peer-Reviewed Original ResearchDose of oritavancinInfective endocarditisTreatment of acute bacterial skinBacterial infectionsLipoglycopeptide antibacterial agentTertiary care medical centreAcute bacterial skinGram-positive bacterial infectionsInvasive bacterial infectionsTreatment failure rateNinety-five adult patientsSoft tissue infectionsProsthetic joint infectionGram-positive organismsBacterial skinDrug discontinuationTissue infectionsRetrospective studyAdult patientsClinical outcomesAdverse eventsOritavancinOff-labelJoint infectionTreat infectionsIs yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas